`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`_______________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`_______________
`
`MEDIVIS, INC.
`Petitioner
`
`v.
`
`NOVARAD CORP.
`Patent Owner
`
`US Patent No. 11,004,271
`
`Inter Partes Review No. IPR2023-00042
`
`_______________
`
`
`PETITIONER’S UPDATED MANDATORY NOTICES
`PURSUANT TO CFR § 42.88
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`ME1 44062253v.1
`
`
`
`Patent No. 11,004,271
`
`
`
`
`Attorney Docket No. 127971-00012
`
`1.
`
`Real Party-in-Interest
`
`The real party in interest for this petition for inter partes review (IPR) is
`
`Medivis, Inc., of 174 5th Avenue, Suite 505, New York, NY, 10010.
`
`2.
`
`Related Matters
`
`On October 13, 2021, Novarad filed a complaint in the District of Delaware
`
`alleging that Medivis infringes U.S. Patent No. 11,004,271 (the ‘271 Patent) and
`
`U.S. Patent No. 10,945,807 (the ‘807 Patent). The Delaware case is designated
`
`C.A. No. 21-1447-GBW. Novarad served the complaint on Medivis on October
`
`14, 2021.
`
`Along with the petition for review of the ‘271 Patent, Medivis also filed a
`
`petition for review of the ‘807 Patent. Like the ‘271 Patent, the ‘807 patent is
`
`owned by Novarad, lists the same two inventors, and is generally directed to
`
`similar AR-assisted surgical navigation methods. Nonetheless, the ‘807 Patent is
`
`not part of the ‘271 Patent family.
`
`Medivis filed its petitions while discovery in the Delaware litigation was in
`
`its early stages. For example, claim construction still has not been briefed, let
`
`alone argued or decided. On December 6, 2022, the parties agreed to stay the
`
`litigation, without prejudice, pending final disposition of the inter partes review
`
`proceedings IPR2023-00042 and IPR2023-00045. The next day, December 7,
`
`2022, the Court ordered the stipulated stay. Thus, the Delaware litigation is now
`
`ME1 44062253v.1
`
`1
`
`
`
`Patent No. 11,004,271
`
`
`
`
`Attorney Docket No. 127971-00012
`
`stayed pending final disposition of the IPR2023-00042 and IPR2023-00045
`
`proceedings.
`
`The ‘271 Patent results from a second continuation of an application that
`
`matured into U.S. Patent 9,892,564. The first continuation of the original parent
`
`matured into U.S. Patent 10,475,244. The ‘271 Patent itself appears to have two
`
`continuations: (1) Application No. 17/316,222 (now U.S. Patent 11,481,987); and
`
`(2) Application No. 17/972,489, filed on October 24, 2022, and is currently
`
`pending.
`
`3.
`
`Counsel and Service Information
`
`Lead Counsel
`
`Back-Up Counsel
`
`Kia Freeman, Reg. No. 47,577
`
`kfreeman@mccarter.com
`
`T: 617-449-6549
`
`
`
`Erik Paul Belt (pro hac vice to be filed)
`
`ebelt@mccarter.com
`
`T: 617-449-6506
`
`John Curran, Reg. No. 50,445
`
`jcurran@mccarter.com
`
`T: 617-449-6519
`
`
`
`All of the foregoing counsel are attorneys at McCarter & English, LLP, 265
`
`Franklin Street, Boston, MA 02110. Medivis consents to service by email at all of
`
`the foregoing email addresses.
`
`
`
`
`
`ME1 44062253v.1
`
`2
`
`
`
`Patent No. 11,004,271
`
`
`
`
`Attorney Docket No. 127971-00012
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Respectfully submitted,
`
`Dated: February 2, 2023
`
`
`
`
`By:
`
`
`
`
`
`
`/s/ Kia Freeman /s/
`Kia L. Freeman
`Registration No. 47,577
`Attorney for Petitioner
`
`
`
`
`
`
`
`
`
`
`
`ME1 44062253v.1
`
`3
`
`
`
`Patent No. 11,004,271
`
`
`
`
`Attorney Docket No. 127971-00012
`
`CERTIFICATE OF SERVICE
`
`The undersigned hereby certifies that a copy of the foregoing was served on
`
`February 2, 2023 by transmitting a copy to the patent owner at the email addresses
`
`identified in the Patent Owner’s Mandatory Notices dated November 2, 2022:
`
`hansen@tnw.com
`brett.davis@tnw.com
`litigation@tnw.com
`
`
`
`
`
`
`
`
`
`
`
`
`By:
`
`
`
`
`/s/ John Curran /s/
`
`John Curran
`Registration No. 50,445
`Attorney for Petitioner
`
`
`
`
`
`
`
`
`
`
`
`
`
`ME1 44062253v.1
`
`4
`
`